Tyrosinase Peptide
Small Size Posterior Uveal Melanoma
National Cancer Institute (NCI)protein_peptidePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Small Size Posterior Uveal Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sargramostim National Cancer Institute (NCI) | Phase 3 | BB |
azd6244 National Cancer Institute (NCI) | Phase 2 | B |
DACARBAZINE National Cancer Institute (NCI) | Phase 2 | B |
Same molecule, other indications
Tyrosinase Peptide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →